Abstract Mesenchymal stem cells (MSCs) have unique properties, including high proliferation rates, self-renewal, multilineage differentiation ability, wide multipotency, hypoimmunogenicity, noninduction of teratomas, and anticancer properties. MSCs can be isolated from embryonic and extraembryonic tissues as well as adult organs. Human Wharton's jelly stem cellconditioned medium possesses anticancer properties and inhibits the growth of solid tumors. Lower oxygen concentration or hypoxic condition can increase the proliferation of MSCs, but there are no differences in surface markers. We determined the osteocyte, chondrocyte, and adipocyte differentiation of normoxic WJMSCs (nor-WJMSCs) and hypoxic 2.5%, hypoxic 5% (hypo-WJMSCs); from a different passage (P4 and P8), we determined the inhibitory effect of WJMSCs-norCM and WJMSCs-hypoCM on the proliferation of human cancer cells including cervical (HeLa), liver (HepG2), prostate (pc3), ovarian (skov3), and oral squamous (hsc3) cancer cell lines compared to normal cells including mouse fibroblast (NIH3T3), human 
Introduction
Umbilical cord matrix contains an inexhaustible, noncontroversial source of stem cells. 1e4 . Postnatal stem cells are offered for use less often because of possible moral/ethical conflict. 4 The umbilical cord mesenchymal stem cells (UCMSCs) derived from human umbilical cord Wharton's jelly (WJMSCs) exhibit low immunogenicity and low immunity after cytotherapy. 5 The UCMSCs are more useful and simpler in donor accessibility isolation, expansion, proliferative capacity, and banking capability; can be used in clinical and experimental therapy 6, 7 ; have a higher proliferation rate and self-renewal capacity than adult tissuederived MSCs 2, 8 ; and a short doubling time. 9, 10 MSCs possess strong immunosuppressive properties and can be used for autologous and allogeneic therapy. 11, 12 Research has shown that MSCs, including UCMSCs, bone marrow MSCs, and adipose tissue MSCs, have anticancer activity and have been shown to inhibit the proliferation of cancer cells in both in vitro and in vivo assays. 5 Hypoxic conditions (1e3% O 2 ) are more beneficial for MSCs because low oxygen tension is more suitable for MSC physiology in the bone marrow (2e7% O 2 ). Previous research has shown that MSCs cultured in hypoxic conditions (2e5% O 2 ) could maintain their viability. 13 The hypoxic microenvironment can lead to a substantial increase in the proliferation rate and population doubling time, but no differences in surface markers of MSCs has been shown. The hypoxic 2.5% O 2 yield has the highest proliferation and the lowest population doubling and population doubling time. 10 The hypoxic condition induces molecular responses including angiogenesis, metabolic change, and metastasis; it also induces the secretion of growth factor and cytokine in MSCs, and elevated the secretion of transforming growth factor-b1 (TGF-b1). In addition, the hypoxic condition can enhance cancer cell growth through the MSCs effect by secretion and expression of TGF-b1. 14 We conducted the continuing research to elucidate the osteocyte, chondrocyte, and adipocyte differentiation of normoxia-treated WJMSCs (nor-WJMSCs) and hypoxiatreated WJMSCs (hypo-WJMSCs) from early and late passage (P4 and P8), to evaluate the WJMSCs-nor conditioned medium (norCM) and WJMSCs-hypoCM toward cancer cell lines including HeLa, HepG2, pc3, skov3, and hsc3 compared to human fibroblast, NIH3T3, and human mesenchymal stem cells (hMSCs).
Materials and methods

Isolation and cultivation of WJMSCs
Isolation and cultivation of MSCs from umbilical cord was as described by Widowati et al, 10 fresh human umbilical cords (UC; n Z 5) were obtained from women aged 25e40 years after full-term births (normal vaginal delivery), all donors signed a written informed consent, and guidelines were approved by the Institutional Ethics Committee at the Stem Cell and Cancer Institute, Jakarta, Indonesia and from the Institutional Ethics Committee collaboration between Maranatha Christian University, Bandung, Indonesia and Immanuel Hospital Bandung, Bandung, Indonesia.
Isolated WJMSCs from UC were rinsed in normal saline (0.9% w/v sodium chloride) and cut into very small explants (1e2 mm), then plated on tissue culture plastic plates. The explants were cultured in minimum essential medium-a with 2 mM GlutaMAX (Invitrogen, Carlsbad, CA, USA), supplemented with 20% fetal bovine serum (FBS; Invitrogen) and penicilline streptomycine amphotericin B (100 U/mL, 100 mg/mL, and 0.25 mg/mL; Invitrogen). Cultures were incubated in a humidified atmosphere with 5% CO 2 at 37 C, replacing medium every 5 days for 21 days. The cells were harvested and replated at a density 8 Â 10 3 cells/cm 2 when cells reached 80e90% confluence. WJMSCs were cultured in 95% air (21% O 2 ), and 5% CO 2 for normoxic and hypoxic conditions (5% O 2 and 2.5% O 2 ).
10,15
Cell surface phenotype and multipotent differentiation
To confirm the effect of oxygen concentration (hypoxia and normoxia) on MSCs characterization. The WJMSCs of passage 4 and 8 (P4 and P8) were characterized the surface marker CD105, CD73, CD90, CD34, CD45, CD14, CD19, and HLA-II using a flow cytometer. WJMSCs at 80% confluence were harvested and dissociated with trypsin-EDTA and centrifuged at 300g for 10 minutes. The pellet was resuspended with phosphate buffered saline (PBS) þ 2% FBS, and cells were counted with a hemocytometer. Between 100 cells and 200 cells in 25 mL PBS were stained with the appropriate surface monoclonal antibodies. Isotype controls were used to determine background staining. These antibodies were as follows: PE (Phycoerythrin) conjugated: CD105 (abcam 53321-100), CD73 (BD550257), CD 90 (abcam 226), CD 34 (BD  348053), CD45 (BD 555482), CD14 (abcam 28061-100), CD 19  (abcam 1168-500), and HLA-DR (abcam 23901); FITCconjugated: mIgG1 (BD349041 and BD 349043), and mIgG2  (BD349053) then added to each FACS tube: isotype mIgG2a-PE, CD105-PE, HLA class II-PE; isotype mIgG1-PE, CD73-PE,  CD19-PE; isotype mIgG1-FITC, CD 34-FITC, CD45-FITC,  CD14-FITC, after incubation 18, 19 Anticancer assay
The cancer cell lines of cervical (HeLa-ATCC CCL-2), liver (HepG2-ATCC HB-8065), prostate (PC3-ATCC CRL-1435), ovarian (SKOV3-ATCC HTB-77), oral squamous (HSC3; ATCC, Manassas, VA, USA), mouse fibroblast (NIH3T3-ATCC CRL-1658), human fibroblast (primary cells), and hMSCs (primary cells from Wharton's jelly) were obtained from Stem Cell and Cancer Institute, Jakarta, Indonesia. The cells were grown and maintained in Dulbecco modified Eagle's medium supplemented with 10% FBS (Invitrogen), 100 U/mL penicillin (Invitrogen), and 100 mg/mL streptomycin (Invitrogen), and incubated at 37 C in a humidified atmosphere and 5% CO 2 .
20,21
The cell viability assay uses an optimized reagent containing resazurin converted to fluorescent resorufin by viable cells that absorbs the light at 490 nm. Briefly, cells were seeded at density 5 Â 10 3 in 96-well plates for 24 hours of incubation 20, 21 ; cells were supplemented by WJMSCs-norCM and WJMSCs-hypoCM in various concentrations (100%, 75%, 50%, and 0%) then incubated for 72 hours. The anticancer activity of WJMSCs-CM was noted for cancer cell lines including HeLa, HepG2, PC3, SKOV3, HSC3. We used NIH3T3, human fibroblast, and hMSCs as controls to determine the cytotoxic effect of WJMSCs-CM in normal cells. MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay (Promega, Madison, WI, USA) was used to determine cell viability. MTS was added at 10 mL to each well. The plate was incubated at 5% CO 2 , 37 C for 4 hours. The absorbance of the cells was measured at 490 nm using a microplate enzyme-linked immunosorbent assay reader (Multiskan Go, Thermo Scientific, USA). The data were presented as number of viable cells and the percentage of viability.
Statistical analysis
To verify the statistical significance of all parameters, the data were calculated and expressed in means and standard deviation (M AE SD). To compare treatments, analysis of variance (ANOVA) was used, and p < 0.05 were considered as statistically significant, along with Tukey honestly significant difference post hoc test and 95% confidence interval. The median inhibitory concentration (IC 50 
Results
MSC markers by cell surface phenotype
Flow cytometry analysis showed that for cultured cells under normoxia and hypoxia (5% O 2 ) for P4 and P8, WJ-MSCs were positive for MSCs marker CD105, CD73, and CD90 and negative for CD34, CD45, CD14, CD19, and HLA-II. The effect of oxygen level (normoxic and hypoxic 5% O 2 ) and passage (early passage P4 and late passage P8) on the surface marker of WJMSCs can be seen in Table 1 . Surface marker expression of WJ-MSCs (P4 and P8) on hypoxia and normoxia were not significantly different (p > 0.05).
MSC differentiation
We examined the differentiation potentials (osteogenic, chondrogenic, and adipogenic differentiation) that were cultured in either normoxic (20% O 2 and 5% CO 2 ) or hypoxic (5% O 2 and 2.5%O 2 ) conditions. After 3 weeks, WJMSCs were cultured in osteogenesis differentiation medium, and the differentiated WJMSCs responses to either normoxia or hypoxia exhibited calcium deposits based on the staining of Alizarin red S. After 2 weeks, WJMSCs were cultured in chondrogenesis differentiation medium, and the differentiated WJMSCs in responses to either normoxia or hypoxia exhibited chondrocyte expression using Alcian blue. After 2 weeks, WJ-MSCs were cultured in adipogensis differentiation medium in response to either normoxia or hypoxia and exhibited lipid droplets using Oil Red O (Fig. 1) . Fig. 1 shows that WJ-MSCs incubated in normoxia (21% O 2 ) and hypoxia (5% O 2 and 2.5% O 2 ) differentiated to osteocyte, adipocyte, and chondrocyte.
Cytotoxic activity
To determine the effect of both WJMSCs-norCM and WJMSCshypoCM toward various cancer cell lines (HeLa, HepG2, PC3, SKOV3, and HSC3) and normal cells (NIH3T3, human fibroblast, and hMSCs), the cell lines were cultured at density 5 Â 10 3 in a 96-well plate. We determined the cell viability by MTS assay. WJMSCs-norCM and WJMSCs-norCM exhibited decreased viability in cancer cell lines in a concentrationdependent manner. The effect of WJMSCs-norCM and WJMSCs-hypoCM on the number of cancer cells can be seen in Table 2 . The number of cancer cells decreased along with treatments, and the higher WJMSCs-CM concentration decreased the number of cancer cells. The effect of WJMSCs-norCM and WJMSCs-hypoCM toward inhibition of cancer cell viability can be seen in Table 3 . As seen in Table  3 , WJMSCs-norCM and WJMSCs-hypoCM could inhibit the proliferation of cancer cells including HeLa, HepG2, PC3, SKOV3, and HSC3 in a concentration-dependent manner.
The IC 50 value of WJMSCs-norCM and WJMSCs-hypoCM (concentration of anticancer candidate, which could inhibit 50% cell proliferation) was found to be 51.690e81.440% (Table 4) . Each sample (WJMSCs-norCM and WJMSCshypoCM) was done in triplicate and inhibition data were analyzed using probit analysis to obtain the IC 50 . As shown in Table 4 , WJMSCs-norCM and WJMSCs-hypoCM exhibited a cytotoxic effect toward HeLa, HepG2, PC3, SKOV3, and HSC3 cells, and the highest anticancer activity was WJMSCshypoCM in HepG2 with IC 50 51 .690% and in HeLa with IC 50 61.425%. The highest anticancer activity of WJMSCs-norCM with IC 50 was 64.424% in HepG2. WJMSCs-hypoCM had higher anticancer activity to inhibit HeLa, HepG2, pc3, and hsc3 cell lines compared to WJMSCs-norCM.
The selective cytotoxic effect of WJMSCs-norCM and WJMSCs-hypoCM was carried out in NIH3T3, human fibroblast, and hMSCs. The effect of WJMSCs-norCM and WJMSCs-hypoCM on the number of normal cells can be seen in Table 5 . The effect of WJMSCs-hypoCM and WJMSCsnorCM on inhibition of normal cells can be seen in Table 6 . The IC 50 value of WJMSCs-norCM and WJMSCshypoCM was found to be 136.290e185.339% ( 
Discussion
WJ-MSCs was positive for CD105, CD73, and CD90 and negative for CD34, CD45, CD14, CD19, and HLA-II (Table 1) . These data were consistent with previous research that hMSCs highly expressed CD105, CD73, 1,10 and CD90 22 and had low expression of CD34, CD45, CD14, CD19, and HLA-II. 1, 10, 22 The surface marker of WJMSCs of P4 and P8 both normoxic and hypoxic 5% O 2 were not significantly different (p > 0.05); these data are consistent with previous research that surface markers expression are positive for CD105, CD73, and CD90 (>95%) and negative for CD34, CD45, CD14, CD19, and HLA-II (<2%). 10, 16 Pluripotency was confirmed by the ability of WJ-MSCs cells to differentiate into osteocytes, chondrocytes, and adipocytes. 24 As demonstrated in Fig. 1 , both nor-WJMSCs and hypo-WJMSCs differentiated to osteocytes, chondrocytes, and adipocytes; these findings were consistent with previous research that MSCs possess an extensive potential to proliferate and differentiate. into osteocytes, adipocytes, and chondrocytes. 22,24e26 MSCs can also be isolated from umbilical cord Wharton's jelly and markers expressed by flow cytometry; differentiate into osteoblast, adipocyte-and chondrocyte-like cells; and exhibit multipotent differentiation potential. 27 After 2 weeks of exposure to adipogenesis induction medium, cells began to show a round shape and most of them contained cytoplasmatic vacuoles, intracellular accumulated lipids, and small oil droplets in the cytoplasm that were positive with Oil Red O staining (Fig. 1B, E , H, K, N, and Q). Control cells grew with proliferative medium were negative with Oil Red O staining (Fig. 1T and W) . 18, 28, 29 These data were validated with previous research, which found that reverse transcription-polymerase chain reaction analysis of adipogenic gene expression also revealed similar degrees of upregulation of lipoprotein lipase, adipocyte fatty acid-binding protein 2 (aP2), and peroxisome proliferator-activated receptor g2 (PPAR g2).
18,30
After 3 weeks of osteogenic induction, the cells produced mineralized matrix by Alizarin red S staining (Fig. 1A , D, G, J, M, and P), cells displayed bone-like nodular aggregates of matrix mineralization, 25 and were absent in control cultures 28 ( Fig. 1S and V) . These data are consistent with those of a previous study finding that reverse transcriptase-polymerase chain reaction analysis of osteogenic gene expression also revealed similar levels of upregulation of osteopontin and osteocalcin. 18 The chondrogenic potential of the MSCs was confirmed with the presence of acidic proteoglycans; it was observed after 2 weeks of chondrogenic differentiation by Alcian blue staining, 23, 31 for chondrogenic extracellular matrix containing hyaluronic acids 31 ( Fig. 1C, F, I , L, O, and R), the negative controls of chondrogenic differentiation of WJMSCs were represented by MSCs of P4 and P8 not cultured into differentiation media 31 ( Fig. 1U and X) . According to Fig. 1 , WJMSCs of early passage and late passage differentiated to osteocytes, chondrocytes, and adipocytes; these data were validated with the previous finding that MSCs could be expanded to 10 or 11 passages. 32 Tables 2e4 show that WJMSCs-norCM and WJMSCs-hypoCM were able to inhibit the proliferation of various cancer cells (cervical, liver, prostate, ovarian, and oral squamosa) with Figure 1 Morphological appearance of osteogenic, adipogenic and chondrogenic differentiation of WJ-norMSCs (normoxiatreated WJ-MSCs) and WJ-hypoMSCs (hypoxia-treated WJ-MSCs) at P4 and P8. For each differentiation protocol, undifferentiated cells were kept as controls (S,T,U,V,W,X). Data are expressed as mean AE standard deviation, different letters in the same row (among concentrations of WJMSCs-norCM, among concentrations of WJMSCs-hypoCM) are significant differences at p < 0.05 (Tukey honestly significant difference post hoc test). FBS Z fetal bovine serum; WJMSCs Z mesenchymal stem cells derived from Wharton's jelly; WJMSCs-hypoCM Z hypoxia-treated WJMSCs conditioned medium; WJMSCsnorCM Z normoxia-treated WJMSCs conditioned medium. The data (inhibition of cancer cells) are expressed as mean AE standard deviation, different superscript letters in the same row (a, b, c, d) are significant differences at p < 0.05 (Tukey honestly significant difference post hoc test). Among the means of groups (type of cancer cell lines in normoxia or hypoxia).
various activities. These data were validated with previous studies that hMSCs can be used for neoplastic transformation and can be developed for novel anticancer therapeutics 33 ; human Wharton's jelly stem cells inhibited certain solid tumors. 4,34e36 UCMSCs significantly inhibit proliferation of cancer cell lines by in vivo and in vitro assay. 4, 37 Unengineered human and rat UC-MSCs significantly attenuate proliferation of breast cancer cell lines in vitro and in vivo, 4 rat mammary tumor cells, 37 human lung cancer cells, 38 mouse Lewis lung carcinoma cells, 39 and mouse pancreatic carcinoma cells. 5, 40 Human umbilical cord mesenchymal stem cells (hUCMSCs) are able to inhibit breast cancer cell proliferation (MDA-MB-231) in a severe combined immunodeficiency (SCID) mouse model through secretion of dickkopf and suppression of the Wnt pathway. 35 hWJMSCs-conditioned medium (hWJSC-CM; 50%) or hWJSCs-cell lysate (hWJSC-CL) 15 mg/mL for 48e72 hours inhibit cancer cell proliferation in breast adenocarcinoma (MDA-MB-231), ovarian carcinoma (TOV-112D), and osteosarcoma (MG-63) cells. The cancer cell lines exhibited cell shrinkage, blebbing, and vacuolations compared to controls. 41 The inhibition was 20e26% and 31e46% for hWJSC-CM and hWJSC-CL, respectively, for all three cancer cell lines. Cell cycle assays show increases in sub-G1 and G2/M phases for all three cancer cell lines suggestive of apoptosis and metaphase arrest. 41 hWJSCs migrated to metastatic tumor sites in the lungs and reduced tumor burden after hWJSCs were administered intravenously 8 days after tumor transplantation in a rat model. 4, 37, 42 Engineered hWJSCs-expressed human interferon-b inhibited breast tumor growth in animal models. 43 hWJSCs inhibit human mammary carcinoma proliferation. 41 Conditioned medium and cell-free lysate of hWJSCs (hWJSC-CM and hWJSC-CL) inhibit the growth of a range of cancer cells, including breast cancer (MDA-MB-231) and ovarian cancer cells (TOV-112D), as well as osteosarcoma cells (MG-63). 41 Exposure of the osteosarcoma cell lines SKES-1 and MG-63 to hWJSC-CL and hWJSC-CM results in cell death and significant growth inhibition in vitro. At the molecular level, there is a simultaneous upregulation of proapoptotic and autophagy-related genes, such as BAX, ATG-5, and BECLIN-1, and downregulation of prosurvival genes, such as BCL-2 and SURVIVIN. In vivo, there was a notable reduction in mammary tumor sizes and weights in immunodeficient mice at 6 weeks after the injections of hWJSC-CL and hWJSC-CM into these tumors. These findings suggest that hWJSC-CL and hWJSC-CM may interfere with the growth of mammary carcinoma and osteosarcoma cells via apoptosis and autophagy. 41 A similar cell death mechanism is observed during co-culture of WJMSCs with the prostate cancer cell line (PC3). In the presence of WJMSCs, PC3 cells exhibit caspase 9/3, PARP, and BAX induction, cJun NH2-terminal kinase (JNK) activation, as well as a decrease in phosphatidylinositol 3-kinase (PI3K)/AKT (also known protein kinase B (PKB)) and extracellular signalregulated kinase (ERK) phosphorylation. Simultaneously, there is a downregulation of prosurvival gene expressions, such as BCL-2, BCL-XL, SURVIVIN, Mcl-1, and cIAP-1.
4,44e47
The tumoricidal activity of hWJSCs-CM is probably mediated by certain soluble factors secreted by these cells into their extracellular environment, such as interleukins, cell adhesion molecules, hyaluronic acid, growth factors, and glycosoaminoglycans. 44, 48, 49 Indeed, proteomic analysis of hWJSC-CM shows significantly high levels of interleukins (IL-1a, IL-6, IL-7, and IL-8), stem cell factor, human growth factor, and intercellular adhesion molecule-1. 44 Moreover, the extracellular matrix of WJMSCs also contains dickkopf-1, a protein known to suppress the Wnt signaling pathway. 35, 48 Likewise, bone marrow MSCs conditioned medium suppresses the proliferation of two hepatoma cell lines in vitro and induces tumor regression in a hepatoma SCID mouse xenograft model by means of Wnt signaling pathway regulations. 45, 47, 48 Engineered bone marrow MSCs are found to secrete IL-12, which inhibits the growth of melanoma and cervical cancer cells through the induction of a tumor-specific T cell response in vivo. 45 Moreover, bone marrow MSCs also express several suicide genes, which halt the proliferation of prostate cancer cells in an athymic murine model. 45 In addition to the upregulation of several proapoptotic and tumor suppressor genes in hWJSCs, transcriptomic studies have also found an increased expression of several cytokines in these cells, such as IL-12a, which are thought to induce apoptosis and thereby mediate the anticancer effects of hWJSCs, hWJSC-CM, and hWJSC-CL. 50, 51 The IL-12 gene promoted the activation of the cellular immune response via expression of a Th1-type cytokine profile and was associated with the inhibition of tumor growth.
3,52 IL-12 treatment represents a novel approach for gene therapy against cervical cancer.
51 IL-8 of hWJSCs killed the cancer cells. 41 Hyaluronan oligosaccharides inhibited the growth of osteosarcoma cell lines (MG-63 and LM-8) 53 and glycosoaminoglyans inhibited the cell proliferation of osteoblasts and osteosarcoma cells. 54 UC-MSCs expressed the multiple tumor suppressor gene. 5 hUCMSC are able to inhibit human breast cancer cells by attenuating primarily the AKT and mitogen-activated protein kinase pathways and stimulating the intrinsic apoptosis pathway. 5 hUCMSC attenuated the growth of cancer cells and mainly by attenuation of Erk-1/2 and PI3K/AKT signaling and intrinsic apoptosis. 5 Nor-WJMSCs and hypo-WJMSCs from P4 and P8 showed no significant differences in MSCs surface marker expression and MSCs differentiation. WJMSCs-norCM and WJMSCshypoCM could inhibit cells proliferation in various cancer cell lines, and were not toxic for normal cells.
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